A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread

CompletedOBSERVATIONAL
Enrollment

79

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

January 16, 2023

Study Completion Date

January 16, 2023

Conditions
Urothelial Carcinoma
Interventions
DRUG

Avelumab

As provided in real world setting

Trial Locations (16)

460-0001

National Hospital Organization Nagoya Medical Center, Nagoya

289-2511

Asahi General Hospital, Asahi

830-0011

Kurume University Hospital, Kurume

503-8502

Ogaki Municipal Hospital, Ōgaki

216-8511

St. Marianna University School of Medicine, Kawasaki

227-8501

SHOWA University Fujigaoka Hospital, Yokohama

634-8522

Nara Medical University Hospital, Kashihara

541-8567

Osaka International Cancer Institute, Osaka

589-8511

Kindai University Hospital, Sayama

431-3192

Hamamatsu University Hospital, Hamamatsu

010-8543

Akita University Hospital, Akita

811-1395

National Hospital Organization Kyushu Cancer Center, Fukuoka

602-8566

University Hospital Kyoto Prefectural University of Medicine IEC, Kyoto

University Hospital Kyoto Prefectural University of Medicine, Kyoto

606-8507

Kyoto University Hospital, Kyoto

930-0194

Toyama University Hospital, Toyama

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY